Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPY072 + bimekizumab
- Development stage
- Phase 2
- Lead developer
- Spyre Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
SPY072 + bimekizumab is an investigational combination regimen consisting of SPY072, a long-acting (half-life-extended) monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A), and bimekizumab, an approved monoclonal antibody targeting interleukin-17A (IL-17A) and interleukin-17F (IL-17F). Developed by Spyre Therapeutics, this combination is being evaluated in the Phase 2 SKYLIGHT trial for the treatment of moderate-to-severe hidradenitis suppurativa (HS). The trial serves as a proof-of-concept study to assess whether dual inhibition of TL1A and IL-17A/F can improve clinical outcomes (such as the week-16 HiSCR75 response rate) compared to bimekizumab alone, supporting the future development of Spyre's planned SPY772 program (a coformulation of SPY072 and SPY007).
- Other names
- bimekizumab + SPY072SPY072 and bimekizumabSPY-072 and bimekizumabSPY 072 and bimekizumabSPY072 in combination with bimekizumabSPY-072 in combination with bimekizumabSPY 072 in combination with bimekizumab
02
Targets
Beyond the preview
Go deeper on SPY072 + bimekizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPY072 + bimekizumab.